Stocktoria
Xilio Therapeutics, Inc. XLO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-22
Xilio Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — |
| R&D expense | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| EPS (diluted) | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 |
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Cash & equivalents | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Shareholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
Source: SEC EDGAR filings · CIK 0001840233 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.